Affiliation:
1. Department of Hematology Tottori Prefectural Central Hospital Tottori Japan
2. Hematology Unit IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola Italy
Abstract
The discovery of driver mutations in myeloproliferative neoplasms has significantly contributed to the management of patients with essential thrombocythaemia (ET). High‐quality evidence has started to pave the way for targeted therapy. The review by Ferrer‐Marín et al. further advances this discussion, highlighting how molecular profiling, including non‐driver gene mutations, is set to revolutionize personalized treatment approaches for ET patients.Commentary on: Ferrer‐Marín et al. Essential thrombocythemia: a contemporary approach with new drugs on the horizon. Br J Haematol 2024;204:1605‐1616.